1. US Food & Drug Administration. FDA approves first treatment for thyroid eye disease [media release]. 21 Jan 2020. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-thyroid-eye-disease.
2. Horizon Therapeutics. TEPEZZA (teprotumumab-trbw) for injection, for intravenous use. 2020. https://www.hzndocs.com/TEPEZZA-Prescribing-Information.pdf. Accessed 2020.
3. Genmab. Genmab announces Rg1507 update [media release]. 4 Dec 2009. http://www.genmab.com.
4. Genmab. Teprotumumab restarts clinical development in new indication [media release]. 11 Jun 2013. http://www.genmab.com.
5. Horizon Pharma. Horizon Pharma plc announces agreement to acquire River Vision Development Corp. and teprotumumab (RV001), a biologic in late-stage development for rare eye disease [media release]. 8 May 2017. http://www.horizonpharma.com.